Patents Assigned to CyDex Pharmaceuticals, Inc.
-
Patent number: 8835407Abstract: The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same.Type: GrantFiled: July 5, 2012Date of Patent: September 16, 2014Assignee: CyDex Pharmaceuticals, Inc.Inventors: Gerold L. Mosher, Stephen G. Machatha, Daniel J. Cushing
-
Patent number: 8829182Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.Type: GrantFiled: March 11, 2013Date of Patent: September 9, 2014Assignee: Cydex Pharmaceuticals, Inc.Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
-
Publication number: 20140221488Abstract: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.Type: ApplicationFiled: December 16, 2013Publication date: August 7, 2014Applicant: CYDEX PHARMACEUTICALS, INC.Inventors: James D. Pipkin, Stephen G. Machatha
-
Publication number: 20140213650Abstract: The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: CYDEX PHARMACEUTICALS, INC.Inventors: James D. Pipkin, Stephen G. Machatha
-
Publication number: 20130197105Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.Type: ApplicationFiled: March 11, 2013Publication date: August 1, 2013Applicant: CyDex Pharmaceuticals, Inc.Inventor: CyDex Pharmaceuticals, Inc.
-
Publication number: 20130184357Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.Type: ApplicationFiled: March 7, 2013Publication date: July 18, 2013Applicant: CyDex Pharmaceuticals, Inc.Inventor: CyDex Pharmaceuticals, Inc.
-
Publication number: 20130129700Abstract: The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution.Type: ApplicationFiled: November 30, 2012Publication date: May 23, 2013Applicant: Cydex Pharmaceuticals, Inc.Inventor: Cydex Pharmaceuticals, Inc.
-
Patent number: 8410077Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.Type: GrantFiled: November 5, 2009Date of Patent: April 2, 2013Assignee: CyDex Pharmaceuticals, Inc.Inventor: Vincent Antle
-
Publication number: 20130059826Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.Type: ApplicationFiled: August 15, 2012Publication date: March 7, 2013Applicant: CyDex Pharmaceuticals, Inc.Inventors: James D. PIPKIN, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher
-
Patent number: 8383606Abstract: SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.Type: GrantFiled: November 5, 2009Date of Patent: February 26, 2013Assignee: CyDex Pharmaceuticals, Inc.Inventor: Vincent Antle
-
Patent number: 8343995Abstract: The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution.Type: GrantFiled: April 26, 2008Date of Patent: January 1, 2013Assignee: Cydex Pharmaceuticals, Inc.Inventors: Gerold L. Mosher, Rebecca L. Wedel, Karen T. Johnson, Stephen G. Machatha, Jane A. Cowee, Daniel J. Cushing
-
Patent number: 8236782Abstract: The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same.Type: GrantFiled: May 13, 2010Date of Patent: August 7, 2012Assignee: Cydex Pharmaceuticals, Inc.Inventors: Gerold L. Mosher, Stephen G. Machatha, Daniel J. Cushing
-
Publication number: 20120164184Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.Type: ApplicationFiled: December 22, 2011Publication date: June 28, 2012Applicant: CyDex Pharmaceuticals, Inc.Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
-
Patent number: 8114438Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.Type: GrantFiled: October 19, 2006Date of Patent: February 14, 2012Assignee: Cydex Pharmaceuticals, Inc.Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
-
Publication number: 20120021013Abstract: An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating diseases, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided.Type: ApplicationFiled: November 7, 2008Publication date: January 26, 2012Applicant: CyDex Pharmaceuticals, Inc.Inventors: Naomi Esaki, James D. Pipkin
-
Patent number: 8049003Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAE-CD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.Type: GrantFiled: April 23, 2008Date of Patent: November 1, 2011Assignee: CyDex Pharmaceuticals, Inc.Inventors: Gerold L. Mosher, James D. Pipkin, Douglas B. Hecker
-
Publication number: 20110251157Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.Type: ApplicationFiled: January 28, 2011Publication date: October 13, 2011Applicant: CyDex Pharmaceuticals, Inc.Inventors: James D. Pipkin, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher
-
Publication number: 20110224232Abstract: A method of treating fungal infection by pulmonary administration of a solution of voriconazole and cyclodextrin is provided The fungal infection can be a pulmonary infection. The solution can be an inhalable aqueous formulation that can be administered via the mouth or nose. The cyclodextrin can be a water soluble cyclodextrin derivative such as sulfoalkyl ether cyclodextrin. The formulation can be administered via a spray device or nebulizer.Type: ApplicationFiled: May 6, 2009Publication date: September 15, 2011Applicants: Board of Regents, The University of Texas System, CyDex Pharmaceuticals, Inc.Inventors: Robert O. Williams III, Rupert O. Zimmerer, Jason T. MxConville, Justin A. Tolman, Nathan P. Wiederhold, Jay I. Peters
-
Publication number: 20110123518Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution; however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.Type: ApplicationFiled: October 14, 2010Publication date: May 26, 2011Applicant: CyDex Pharmaceuticals, Inc.Inventors: James D. Pipkin, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher
-
Publication number: 20110008325Abstract: An inhalable unit dose liquid formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of corticosteroid, such as budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. The formulation is prepared by mixing SAE-CD, in solid or liquid (dissolved) form, with an inhalable suspension-based unit dose formulation.Type: ApplicationFiled: July 13, 2010Publication date: January 13, 2011Applicant: CyDex Pharmaceuticals, Inc.Inventors: James D. Pipkin, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher